Accéder au contenu
Merck
Toutes les photos(3)

Key Documents

View All Documentation

SAB4200778

Sigma-Aldrich

Anti-NRAS (internal) antibody produced in rabbit

affinity isolated antibody

Synonyme(s) :

Anti-GTPase NRas, Anti-transforming protein N-Ras

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(3)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

200

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

predicted mol wt ~21 kDa

Espèces réactives

human

Concentration

~1.0 mg/mL

Technique(s)

immunoblotting: 2.5-5 μg/mL using human MCF7 cell line extract
immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human melanoma sections

Numéro d'accès UniProt

P01111

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... NRAS(4893)

Description générale

NRAS, also known as GTPase NRas, Transforming protein N-Ras, or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family, together with KRAS (Kirsten RAS), and HRAS (Harvey RAS), comprising a family of low-molecular-weight GTPases. The Ras family is named for a retrovirus that induced rat sarcomas that were later found to have activating RAS mutations. Ras family proteins serve as molecular switches in regulating pathways that are responsible for diverse cellular processes such as proliferation, differentiation, migration, and apoptosis.3 Ras proteins are highly homologous regarding their primary amino acid sequence and the differences among them concentrated in their C-terminal region. Anti-NRAS (internal) antibody produced in rabbit specifically recognizes human NRAS and does not cross-react with KRAS.

Immunogène

Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH

Application

The antibody may be used in various immunochemical techniques including immunoblotting (predicted ∼21 kDa) and immunohistochemistry. Detection of the NRAS band by Immunoblotting is specifically inhibited by the immunizing protein.

Forme physique

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as preservative.

Autres remarques

This product is for R&D use only, not for drug, household, or other uses.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Ahmed A Samatar et al.
Nature reviews. Drug discovery, 13(12), 928-942 (2014-12-02)
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique